EMAIL THIS PAGE TO A FRIEND

Journal of labelled compounds & radiopharmaceuticals

Radioiodination and biological evaluation of candesartan as a tracer for cardiovascular disorder detection.


PMID 27634455

Abstract

The goal of the study aims to evaluate newly radioiodinated candesartan (CAN) as a potential cardiovascular tracer. CAN was labeled using (125) I with chloramine-T (Ch-T) and N-bromosuccinimide (NBS) with full characterization of cold Iodo-candesartan. Factors such as pH, reaction temperature, reaction time, substrate, and oxidizing agent amounts were studied to optimize the radioiodination of CAN. The optimum radiochemical yield of (125) I-CAN was 98%. The labeled compound was separated and purified using high-pressure liquid chromatography. The biological distribution indicates the suitability of (125) I-CAN as a novel tracer to detect cardiovascular disorders.